Immunity and bacterial colonisation in bronchiectasis

Thorax

Volumn 67, Issue 11, 2012, Pages 1006-1013

  Whitters, Deborah ^a   Stockley, Robert ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN G; TOLL LIKE RECEPTOR;

ADAPTIVE IMMUNITY; BACTERIAL COLONIZATION; BACTERIUM ADHERENCE; BIOFILM; BRONCHIECTASIS; DISEASE ASSOCIATION; DRUG RESPONSE; HOST RESISTANCE; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INNATE IMMUNITY; LOWER RESPIRATORY TRACT; MOLECULAR INTERACTION; NEUTROPHILIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; REVIEW;

EID: 84868207364     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2011-200206     Document Type: Review

References (75)

1. Pasteur MC, Helliwell SM, Houghton SJ, et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000;162:1277-84.
2. Martinez-Garcia MA, Perpiná-Tordera M, Román-Sánchez P, et al. Quality of life determinants in patients with clinically stable bronchiectasis. Chest 2005;128:739-45. (Pubitemid 41140504)
3. Patel IS, Vlahos I, Wilkinson TM, et al. Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:400-7. (Pubitemid 39214614)
4. Cole P, Wilson R. Hostemicrobial interrelationships in respiratory infection. Chest 1989;95:217Se21S.
5. Nicod LP. Pulmonary defence mechanisms. Respiration 1999;66:2-11. (Pubitemid 29089985)
6. Loebinger MR, Bilton D, Wilson R. Upper airway 2: bronchiectasis, cystic fibrosis and sinusitis. Thorax 2009;64:1096-101.
7. Rogan MP, Geraghty P, Green CM, et al. Antimicrobial proteins and polypeptides in pulmonary inate defence. Respir Res 2006;7:29.
8. Pilette C, Detry B, Guisset A, et al. Dual effect of neutrophils on secretory component production by human bronchial epithelial cells. Eur Resp Rev 2006;15:175-6.
9. Burnett D, Crocker J, Stockley RA. Cells containing IgA subclasses in bronchi of subjects with and without chronic obstructive pulmonary disease. J Clin Path 1987;40:1217-20. (Pubitemid 17153815)
10. Burnett D, Hill SL, Bradwell AR. IgA subclasses in sputum from patients with bronchiectasis. Respir Med 1990;84:123-7. (Pubitemid 20170162)
11. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95.
12. Hiemstra PS. Antimicrobial peptides in the real world: implications for cystic fibrosis. Eur Respir J 2007;29:617-18. (Pubitemid 46554607)
13. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004;23:327-33. (Pubitemid 38195522)
14. Cowburn AS, Condliffe AM, Farahi N, et al. Advances in neutrophil biology: clinical implications. Chest 2008;134:606-12.
15. Stockley RA. Neutrophils and the pathogenesis of COPD. Chest 2002;121:151Se5S.
16. Litzman J, Freiberger T, Grimbacher B, et al. Mannose-binding lectin gene polymorphic variants predispose to the development of bronchopulmonary complications but have no influence on other clinical and laboratory symptoms or signs of common variable immunodeficiency. Clin Exp Immunol 2008;153:324-30.
17. Fevang B, Mollnes TE, Holm AM, et al. Common variable immunodeficiency and the complement system; low mannose-binding lectin levels are associated with bronchiectasis. Clin Exp Immunol 2005;142:576-84. (Pubitemid 41719855)
18. Mikami M, Llewellyn-Jones CG, Bayley D, et al. The chemotactic activity of sputum from patients with bronchiectasis. Am J Respir Crit Care Med 1998;157:723-8.
19. Borregaard N, Theilgaard-Mönch K, Sørensen OE, et al. Regulation of human neutrophil granule protein expression. Curr Opin Hematol 2001;8:23-7. (Pubitemid 32047658)
20. Mitchell T, Lo A, Logan MR, et al. Primary granule exocytosis in human neutrophils is regulated by Rac-dependent actin remodelling. Am J Physiol Cell Physiol 2008;295:C1354-65. (Pubitemid 352790350)
21. Tung JP, Fraser JF, Wood P, et al. Respiratory burst function of ovine neurophils. BMC Immunol 2009;10:25.
22. Reeves EP, Lu H, Jacobs HL, et al. Killing activity of neutrophils is mediated through activation of proteases by flux. Nature 2002;416:291-7. (Pubitemid 34260237)
23. Rosenzweig SD. Inflammatory manifestations in chronic granulomatous disease. J Clin Immunol 2008;28:S67-72.
24. Godoy MC, Vos PM, Cooperberg PL, et al. Chest radiographic and CT manifestations of chronic granulomatous disease in adults. Am J Roetgenol 2008;191:1570-5.
25. King PT, Hutchinson P, Holmes PW, et al. Assessing immune function in adult bronchiectasis. Clin Exp Immunol 2006;144:440-6. (Pubitemid 43799927)
26. Akira S, Hummi H. Recognition of pathogen associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95. (Pubitemid 36071561)
27. Droemann D, Goldmann T, Branscheid D, et al. Toll like receptor 2 is expressed by alveolar epithelial cells type II and macrophages in the human lung. Histochem Cell Biol 2003;119:103-8. (Pubitemid 36308093)
28. Chaudhuri N, Dower S, Whyte M, et al. Toll like receptors and chronic lung disease. Clin Sci 2005;109:125-33. (Pubitemid 41117295)
29. Takeda K, Akira S. Roles of toll like receptors in innate immune responses. Genes Cells 2001;6:733-42. (Pubitemid 32894068)
30. Netea M, Van der Graaf C, Van der Meer JW, et al. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system. J leukoc Biol 2004;75:749-55. (Pubitemid 38580054)
31. Review Toll-Like Receptors (TLRs) online. 2008. http://www. SABiosciences.com/patheway.php?sn=Toll-like-receptor (accessed Mar. 2011).
32. Akira S. Toll-like receptors: lessons from knockout mice. Biochem Soc Trans 2000;28:511-56.
33. Martinez-Garcia MA, Soler-Cataluńna JJ, Perpińná- Terdera M, et al. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-72. (Pubitemid 350156014)
34. Evans SA, Turner SM, Bosch BJ, et al. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9:1601-4. (Pubitemid 26271139)
35. Ho PL, Chan KN, Ip MS, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998;114:1594-8. (Pubitemid 128487481)
36. Skerrett SJ, Wilson CB, LIggitt HD, et al. Redundant toll like receptor signalling in the pulmonary host response to Pseudomonas aeruginosa. Am J Physiol Lung Cell Mol Physiol 2007;292:L312-22. (Pubitemid 46103456)
37. Adamo R, Sokol S, Soong G, et al. Pseudomonas flagella activate airway epithelial cells through toll like receptor 5. Am J Respiratory Cell Mol Biol 2004;30:627-34.
38. Koller B, Kappler M, Latzin P, et al. The expression on neutrophils at the pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in cystic fibrosis lung disease. J Immunol 2008;18:2753-63.
39. Wang X, Moser C, Louboutin JP, et al. Toll like receptor 4 mediates immune response to Haemophilus influenzae infection in the mouse lung. J Immunol 2002;168:810-15. (Pubitemid 34049582)
40. Simpson JL, Grissell TV, Douwes J, et al. Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 2007;62:211-18. (Pubitemid 46579799)
41. Tokairin Y, Shibata Y, Sata M, et al. Enhanced immediate inflammatory response to Streptococcus pneumoniae in the lungs of mice with pulmonary emphysema. Respirology 2008;13:324-32. (Pubitemid 351503133)
42. Moore BB, Moore TA, Toews GB. Role of T and B lymphocytes in pulmonary host defence. Eur Respir J 2001;18:846-56. (Pubitemid 33076928)
43. International Union of Immunological Societies. Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol 1999;118:S1-28.
44. Kainulainen L, Varpula M, Liippo K, et al. Pulmonary abnormalities in patients with primary hypogammaglobulinaemia. J Allergy Clin Immunol 1999;104:1031-6. (Pubitemid 29532125)
45. Quinti I, Soresina A, Spadoro G, et al. Long term follow up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol 2007;27:308-16. (Pubitemid 46790816)
46. Tarzi MD, Grigoriadous S, Carr SB, et al. Clinical immunology review series: an approach to the management of pulmonary disease in primary antibody deficiency. Clin Exp Immunol 2009;155:147-55.
47. Chapel HM. Consensus on diagnosis and management of primary antibody deficiencies. Consensus panel for the diagnosis and management of primary antibody deficiencies. BMJ 1994;308:581-5.
48. Buckley R. IgG subclass deficiency - IDF Clinical Focus on Primary Immune Deficiencies. 1998;1:1-4. http://primaryimmune.org/publications?aid= 409&pid= 275&sa=1 (accessed Sep. 2011).
49. Hill SL, Mitchell JL, Burnett D, et al. IgG subclasses in the serum and sputum of patients with bronchiectasis. Thorax 1998;53:463-8. (Pubitemid 28308061)
50. Stead A, Douglas JG, Broadfoot CJ, et al. Humoral immunity and bronchiectasis. Clin Exp Immunol 2002;130:325-30. (Pubitemid 35286222)
51. Vendrell M, deGracia J, Rodrigo MJ, et al. Antibody production deficiency with normal IgG levels in bronchiectasis of unknown aetiology. Chest 2005;127:197-204. (Pubitemid 41724577)
52. Conley ME, Rohrer J, Minegishi Y. X-linked agammaglobulinaemia. Clin Rev Allergy Immunology 2000;19:183-204.
53. Horn J, Thon V, Bartonkova D, et al. Anti-IgA antibodies in common variable immunodeficiency (CVID): diagnostic workup and therapeutic strategy. Clin Immunol 2007;122:156-62. (Pubitemid 46073896)
54. Waisbren BA, Brown I. A factor in the serum of patients with persisting infection that inhibits the bactericidal activity of normal serum against the organism that is causing the infection. J Immunol 1966;97:431-7.
55. Guttman RM, Waisbren BA. Bacterial blocking activity of specific IgG in chronic pseudomonas infection. Clin Exp Immunol 1975;19:121-30.
56. Hornick DB, Fick RB. The immunoglobulin G subclass composition of immune complexes in cystic fibrosisdimplications for the pathogenesis of the pseudomonas lung lesion. J Clin Invest 1990;86:1285-92. (Pubitemid 20370436)
57. Thomassen MJ, Demko CA. Serum bactericidal effect on Pseudomonas aeruginosa isolates from cystic fibrosis patients. Infect Immun 1981;33:512-18. (Pubitemid 11042664)
58. Maclennan CA, Gilchrist JJ, Gordon MA, et al. Dysregulated humoral immunity to nontyphoidal salmonella in HIV infected African adults. Science 2010;328:508-12.
59. Asad S, Opal S. Bench-to-bedside review: Quorum sensing and the role of cell to-cell communication during invasive bacterial infection. Crit Care 2008;12:236.
60. Popat R, Crusz SA, Diggle SP. The social behaviours of bacterial pathogens. Br Med Bull 2008;87:63-75.
61. Bjarnsholt T, Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem 2007;387:409-14. (Pubitemid 46067458)
62. Telford G, Wheeler D, Williams P. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone has immunomodulatory activity. Infect Immun 1998;66:36-42.
63. Ritchie AJ, Jansson A, Stallberg J, et al. The Pseudomonas aeruginosa Quorumsensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone inhibits T-Cell differentiation and cytokine production by a mechanism involving an early step in TCell activation. Infect Immun 2005;73:1648-55. (Pubitemid 40470753)
64. Smith RS, Harris SG, Phipps R, et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone contributes to virulence and induces inflammation in vivo. J Bacteriol 2002;184:1132-9. (Pubitemid 34113382)
65. Tateda K, Ishii Y, Horikawa M, et al. The Pseudomonas aeruginosa quorum-sensing signal molecule N-(3-oxododecanoyl)-L-homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect Immun 2003;71:5785-93. (Pubitemid 37205632)
66. Donlan R, Costerton J. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002;15:167-93. (Pubitemid 34303762)
67. deKievit TR. Quorum sensing in Pseudomonas aeruginosa biofilms. Environ Microbiol 2009;11:279-88.
68. Bryers JD. Medical biofilms. Biotechnol Bioeng 2008;100:1-18. (Pubitemid 351579011)
69. Parsek MR. Biofilms 2003: emerging themes and challenges in studies of surface-associated microbial life. J Bacteriol 2004;186:4427-40. (Pubitemid 38891005)
70. Patriquin GM, Banin E, Gilmour C, et al. Influence of quorum sensing and iron twitching motility and Biofilm formation in Pseudomonas aeruginosa. J. Bacteriol 2008;190:662-71. (Pubitemid 351360082)
71. Klausen M, Heydorn A, Ragas P, et al. Biofilm formation by Pseudomonas aeruginosa wild type flagella and type IV pili mutants. Mol Microbiol 2003;48:1511-24. (Pubitemid 36751058)
72. Davies DG, Parsek MR, Pearson JP, et al. The involvement of cell to cell signals in the development of a bacterial biofilm. Science 1998;280:295-8. (Pubitemid 28178075)
73. Shrout JD, Chopp DL, Just CL, et al. The impact of quorum sensing and swarming motility on Pseudomonas aeruginosa biofilm formation is nutritionally conditional. Mol Microbiol 2006;62:1264-77. (Pubitemid 44707193)
74. Walker TS, Tomlin KL, Worthen GS, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005;73:3693-701. (Pubitemid 40745914)
75. Winstanley C, Fothergill JL. The role of quorum sensing in chronic cystic fibrosis Pseudomonas aeruginosa infections. FEMS Microbiol Lett 2009;290:1-9.